Clamoxyl I.V.-I.M. is available again. The recommendations formulated by the FAMHP and the NIHDI for rational use by hospital pharmacists and physicians-specialists no longer apply. The marketing of Clamoxyl I.V.-I.M. and of Augmentin I.V. will eventually be definitively discontinued.
Clamoxyl I.V.-I.M. is available again.
The company GSK has reported to the FAMHP that Clamoxyl I.V.–I.M. has been available again since 7 January 2020. The recommendations of the FAMHP and the NIHDI to limit the use of Clamoxyl I.V.–I.M. to the three indications for which no suitable alternatives are available no longer apply.
Clamoxyl I.V.-I.M. and Augmentin I.V. definitive discontinuation of marketing
The company GSK also reported that the production of Augmentin I.V. will be phased out by the end of 2020, and that of Clamoxyl I.V.-I.M. by the end of 2021.
Injectable amoxicillin (Clamoxyl I.V.-I.M.) and injectable amoxicillin/clavulanic acid (Augmentin I.V) are essential medicines. Therefore, the FAMHP considers it essential to seek sustainable solutions as a matter of priority, so that patients have access to a suitable treatment even after discontinuation of marketing.
For Augmentin I.V. generic alternatives are available on the Belgian market.
For Clamoxyl I.V.–I.M. there is currently no alternative available on the Belgian market. The FAMHP is working closely with GSK and other possible suppliers to find a solution for the situation.
The oral forms of the Augmentin and Clamoxyl range remain available on the Belgian market.